Fundraising FoxIksuda Therapeutics
1 known investors
Find your way into Iksuda Therapeutics
Sign up to find every way you can get introduced to Iksuda Therapeutics
- Your email: who you already know at Iksuda Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Iksuda Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Iksuda develops antibody-drug conjugates (ADCs) with enhanced tumor specificity for treating difficult-to-treat cancers. The company designs class-leading ADC therapeutics incorporating novel payloads and platform technologies optimized for anti-cancer efficacy and patient safety.
Investors · 1
Premier Partnerslisted by Premier PartnersSeoul
How we know: Premier Partners's portfolio page · press coverage · Not right? Tell us
In the news
Frequently asked questions
- What does Iksuda Therapeutics do?
- Iksuda develops antibody-drug conjugates (ADCs) with enhanced tumor specificity for treating difficult-to-treat cancers. The company designs class-leading ADC therapeutics incorporating novel payloads and platform technologies optimized for anti-cancer efficacy and patient safety.
- Who are Iksuda Therapeutics's investors?
- Iksuda Therapeutics's investors include Premier Partners.